Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

CG Oncology (CGON) EBT Margin: 2023-2025

Historic EBT Margin for CG Oncology (CGON) over the last 2 years, with Sep 2025 value amounting to -2,623.53%.

  • CG Oncology's EBT Margin rose 4482531.00% to -2,623.53% in Q3 2025 from the same period last year, while for Sep 2025 it was -6,828.64%, marking a year-over-year increase of 381302.00%. This contributed to the annual value of -7,729.76% for FY2024, which is 1606681.00% up from last year.
  • Per CG Oncology's latest filing, its EBT Margin stood at -2,623.53% for Q3 2025, which was up 96.04% from -66,263.46% recorded in Q1 2025.
  • CG Oncology's EBT Margin's 5-year high stood at -2,623.53% during Q3 2025, with a 5-year trough of -1,655,100.00% in Q4 2023.
  • Over the past 3 years, CG Oncology's median EBT Margin value was -17,036.04% (recorded in 2024), while the average stood at -214,864.91%.
  • In the last 5 years, CG Oncology's EBT Margin skyrocketed by 164,812,544bps in 2024 and then plummeted by 6,306,403bps in 2025.
  • CG Oncology's EBT Margin (Quarterly) stood at -1,655,100.00% in 2023, then soared by 164,812,544bps to -6,974.56% in 2024, then spiked by 4,482,531bps to -2,623.53% in 2025.
  • Its EBT Margin was -2,623.53% in Q3 2025, compared to -66,263.46% in Q1 2025 and -6,974.56% in Q4 2024.